


QUALITY TRANSFORMATION INITIATIVE


Measurement Year 2024 | Year 2 Results

QUALITY TRANSFORMATION INITIATIVE



*Public purchasers includes CalPERS and DHCS/Medi-Cal

AN ALIGNED STATE-WIDE APPROACH



EQUITY-CENTERED OUTCOMES MEASURES

Core Measures	Clinical Context
Blood Pressure	Key risk factor for cardiovascular disease (heart attacks and strokes) & the leading cause of death in the United States. BP control rates are ~10% lower for Asian, Black and Hispanic people than White counterparts. Black Americans have 4-5 times greater hypertension-related mortality than White counterparts
Diabetes (A1c control)	~50% Californians have prediabetes or diabetes, which is a leading cause of blindness and amputation and key risk factor for cardiovascular disease. It is 2x more prevalent among Black, AI/AN, and Hispanic people than Whites. Diabetes death was 3x higher among Black and NH/PI than White counterparts
Colorectal Cancer Screening	Cancer is the second leading cause of death after heart disease, and colorectal cancer is the second leading cause of cancer death after lung cancer. Black Americans are 20% more likely to get colorectal cancer and 40% more likely to die from it than others. Screening reduces the risk of developing and dying from CRC cancer by 60-70%
Childhood Immunizations	Childhood immunizations prevent 10.5m diseases annually. Black, Hispanic, AI/AN children have lower vaccine coverage than White children. For every \$1 spent on immunizations, there is as much as \$29 in savings

YEAR 2 (MY2024) QTI OVERVIEW

Contract Period:

- 2023-2025 Covered California QHP IND Issuer Contract

Measures Assessed:

- Controlling High Blood Pressure (CBP)
- Glycemic Status Assessment for Patients with Diabetes (GSD) Glycemic Status <8.0%
- Colorectal Cancer Screening (COL)
- Childhood Immunization Status (Combo 10)

Issuers Assessed:

- 13 issuer products from 10 issuers

Percent Premium at Risk:


- 1.8% of total Gross Premium per product per measure

QHP Issuers Participating in QTI

MY2023	MY2024	MY2025	MY2026
Anthem	Anthem	Aetna	Anthem
Blue Shield	Blue Shield	Anthem	Blue Shield
CCHP	CCHP	Blue Shield	CCHP
Health Net	Health Net	CCHP	Health Net
Kaiser	Kaiser	Health Net	IEHP
LA Care	LA Care	Kaiser	Kaiser
Molina	Molina	LA Care	LA Care
Sharp	Sharp	Molina	Molina
VHP	VHP	Sharp	Sharp
WHA	WHA	VHP	VHP
		WHA	WHA


CHRONIC DISEASE CONTROL AND CANCER SCREENING RATES CONTINUE TO IMPROVE IN YEAR 2

CBP



11 of 13 Issuer products had an **increase** in score for **controlling blood pressure**

HbA1c <8%



10 of 13 Issuer products had an increase in score for **diabetes management**

COL



9 of 13 Issuer products had an **increase** in score for **colorectal cancer screening**

YEAR 2: COVERED CALIFORNIA-WIDE IMPACT OF QTI

Diabetes Control (A1c <8)

13/13 Issuer Products performed at or above the MY2021 66th percentile, accounting for **100% of members** in the measured population

Colorectal Cancer Screening (COL)

6/13 Issuer Products performed at or above the MY2021 66th percentile, accounting for **71% of members** in the measured population

Controlling Blood Pressure (CBP)

8/13 Issuer Products performed at or above the MY2021 66th percentile, accounting for **83% of members** in the measured population


ALL PLANS ACHIEVED GOAL FOR DIABETES CONTROL

	HbA1c Control MY2023	HbA1c Control MY2024	HbA1c Delta	COL MY2023	COL MY2024	COL Delta	CBP MY2023	CBP MY2024	CBP Delta
Number of issuer products at goal*	10/13	13/13	+3	5/13	6/13	+1	6/13	8/13	+2
Percentage of members in the measured population at goal	86%	100%	+14%	51%	71%	+20%	63%	89%	+26%

*QTI uses MY2021 national exchange 66th percentile as goal for these 3 measures

FORWARD PROGRESS ON ALL, EXCEPT FOR CIS-10

There has been a year-over-year increase in the number of products reaching the QTI goal of the 66th Percentile for HbA1c, COL, and CBP



For MY2023 and 2024 13 issuer products were eligible for all QTI measures except CIS-10 where only 10 products were eligible


YEAR TWO REAFFIRMS SUCCESS OF QTI, WITH CONTINUED HEADWINDS ON VACCINE UPTAKE

	Overall Population % Improvement (MY23 to MY24)
Diabetes Control: A1c <8%	+6.35%
Colorectal Cancer Screening	+6.23%
Blood Pressure Control	+2.73%
Childhood Immunization: CIS-10*	-42.61%


PLAN REPORTED ACTIVITIES FOR QTI

Category	Example Activities Deployed by QHPs	# of QHPs
Internal Organizational Changes	• Restructured population health equity and quality teams • Created internal equity workgroups and leadership training • Formed formal health equity committees	4
Direct-to-Member Programs & Incentives	• Text messaging and mailer campaigns • New wellness incentives and rewards programs	5
Provider Network & Contract Enhancements	• Added equity clauses and QTI metrics in contracts • Incorporated equity measures in VBP models • Deployed provider education sessions	6
Technology & Data Exchange Innovations	• Launched equity dashboards with stratified data • Improved member matching via CAIR unique ID • Enhanced EHR alerts and real-time gap reporting • Modernized data systems for equity analytics	7
Performance Monitoring & Accountability	• HEDIS dashboards tracking equity metrics • Regular disparity reviews (e.g., maternal health) • Equity goals tied to performance reviews	7
Health Disparities & Equity-Focused Efforts	• Partnered with BIPOC-led organizations and universities • Expanded doula and cultural outreach services • Introduced equity-focused provider scorecards	8
Other	• Youth outreach and school partnerships • Innovation pilots and internal sprints • Collaborations with CBOs and local health departments	5


MY2024: DIABETES CONTROL ABOVE 66TH PERCENTILE FOR ALL 13 ISSUER PRODUCTS




MY2024: COLON CANCER SCREENING CONTINUES TO IMPROVE, NO ISSUER BELOW 25TH PERCENTILE



MY2024: BLOOD PRESSURE CONTROL CONTINUES TO IMPROVE ACROSS 11 ISSUER PRODUCTS






MY2024: FOR CHILDHOOD IMMUNIZATION, ONLY ONE ISSUER ABOVE 66TH PERCENTILE



NATIONAL DECLINES ON CHILDHOOD IMMUNIZATION

National CIS-10 Trends



Factors that contribute to low performance on CIS-10 measure:

- Caregiver vaccine fatigue after COVID-19
- Healthcare systems are struggling with access in primary care and declines in usual source of care persist
- Declining vaccine confidence
- Variation in immunization guidance (federal vs state)
- CDC allowable catch-up schedule is not fully captured in CIS-10 measure specifications

QTI ADJUSTMENTS BASED ON ISSUER FEEDBACK

CIS10 Allowance Program

- MY2023 Launch: Allowed issuers to submit supplemental data for children completing the full vaccine series, even if the 2nd flu shot was given after the 2nd birthday (90 days).
- MY2024 Expansion: Now includes all CIS10 vaccines. Vaccinations accepted up to 180 days post-2nd birthday. Designed in response to issuer request and to maintain clinical appropriateness.

CIS10 Payment Adjustment


- For MY2024, Issuers may choose to retain 50% of each product's CIS10 QTI payment. Funds can support issuer-led quality improvement activities. The 50% reduction is applied after CIS10 Allowance Program assessed.
- Issuers must discuss plans with Covered California before committing funds to ensure alignment with program criteria and goals. Issuers must submit 2026 mid-year and end-of year reports outlining quantitative accounting of funds spent and a signed attestation of accuracy by QHP issuer leadership.
- Covered California may continue program in MY2025 depending on issuer adherence to guidelines and impact of funds.

QHP PERMISSIBLE USES OF RETAINED FUNDS

- ✓ Boosting childhood immunization rates and well-child visits
- ✓ Expanding pediatric and adult preventive care access
- ✓ Reducing health disparities among children and vulnerable groups
- ✓ Supporting vaccine outreach and education
- ✓ Strengthening immunization data systems
- ✓ Investing in primary care workforce


ESTIMATED 2026 QTI PAYMENT

MY2024 QTI Funds by Measure




WHILE STRONG OVERALL PERFORMANCE, BLOOD PRESSURE CONTROL VARIES ACROSS SUBPOPULATIONS

Controlling Blood Pressure (CBP) Performance by Race/Ethnicity
Measurement Year 2024




NO SUBPOPULATION BELOW 25TH PERCENTILE FOR DIABETES CONTROL

HbA1C < 8% Performance by Race/Ethnicity
Measurement Year 2024




CONTINUED EFFORT NEEDED TO IMPROVE COLON CANCER SCREENING RATES ACROSS ALL SUBPOPULATIONS

Colorectal Cancer Screening (COL) Performance by Race/Ethnicity
Measurement Year 2024



PRONOUNCED DIFFERENCES IN CHILD IMMUNIZATION RATES BY SUBPOPULATION

Childhood Immunizations (CIS 10) Performance by Race/Ethnicity
Measurement Year 2024



Because Kaiser submits full Commercial population data (n ~ 2,060) while most other Issuers submit a hybrid sample (≤ 411), Kaiser’s large sample size significantly influences the rate, so views are shown with and without Kaiser included. Blank data points are counts too low to report.

THANK YOU